These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28606922)

  • 1.
    De La Maza L; Wu M; Wu L; Yun H; Zhao Y; Cattral M; McCart A; Cho BJ; de Perrot M
    Clin Cancer Res; 2017 Sep; 23(18):5502-5513. PubMed ID: 28606922
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
    Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
    Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.
    Dovedi SJ; Cheadle EJ; Popple AL; Poon E; Morrow M; Stewart R; Yusko EC; Sanders CM; Vignali M; Emerson RO; Robins HS; Wilkinson RW; Honeychurch J; Illidge TM
    Clin Cancer Res; 2017 Sep; 23(18):5514-5526. PubMed ID: 28533222
    [No Abstract]   [Full Text] [Related]  

  • 4. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 5. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.
    Wu L; Yun Z; Tagawa T; Rey-McIntyre K; de Perrot M
    Mol Cancer Ther; 2012 Aug; 11(8):1809-19. PubMed ID: 22584123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foxp3
    Kohno M; Murakami J; Wu L; Chan ML; Yun Z; Cho BCJ; de Perrot M
    J Immunol; 2020 Nov; 205(9):2519-2531. PubMed ID: 32948683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
    Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
    [No Abstract]   [Full Text] [Related]  

  • 8. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
    Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences.
    Calabrò L; Ceresoli GL; D'Incecco A; Scherpereel A; Aerts J; Maio M
    Cytokine Growth Factor Rev; 2017 Aug; 36():25-31. PubMed ID: 28736182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.
    Wu L; Wu MO; De la Maza L; Yun Z; Yu J; Zhao Y; Cho J; de Perrot M
    Oncotarget; 2015 May; 6(14):12468-80. PubMed ID: 25980578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation.
    Jing H; Hettich M; Gaedicke S; Firat E; Bartholomä M; Niedermann G
    J Immunother Cancer; 2019 Feb; 7(1):55. PubMed ID: 30808414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
    Reardon DA; Gokhale PC; Klein SR; Ligon KL; Rodig SJ; Ramkissoon SH; Jones KL; Conway AS; Liao X; Zhou J; Wen PY; Van Den Abbeele AD; Hodi FS; Qin L; Kohl NE; Sharpe AH; Dranoff G; Freeman GJ
    Cancer Immunol Res; 2016 Feb; 4(2):124-35. PubMed ID: 26546453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
    Marciscano AE; Ghasemzadeh A; Nirschl TR; Theodros D; Kochel CM; Francica BJ; Muroyama Y; Anders RA; Sharabi AB; Velarde E; Mao W; Chaudhary KR; Chaimowitz MG; Wong J; Selby MJ; Thudium KB; Korman AJ; Ulmert D; Thorek DLJ; DeWeese TL; Drake CG
    Clin Cancer Res; 2018 Oct; 24(20):5058-5071. PubMed ID: 29898992
    [No Abstract]   [Full Text] [Related]  

  • 17. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
    de Goeje PL; Klaver Y; Kaijen-Lambers MEH; Langerak AW; Vroman H; Kunert A; Lamers CHJ; Aerts JGJV; Debets R; Hendriks RW
    Front Immunol; 2018; 9():2034. PubMed ID: 30245692
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
    Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA
    Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CTLA-4 therapy for malignant mesothelioma.
    Guazzelli A; Bakker E; Krstic-Demonacos M; Lisanti MP; Sotgia F; Mutti L
    Immunotherapy; 2017 Mar; 9(3):273-280. PubMed ID: 28231719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.